Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson’s Disease Treatment will Boost Market Despite Patent Cliff

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson’s Disease Treatment will Boost Market Despite Patent Cliff”. A highly dynamic market scenario is expected in Neurodegenerative diseases in the next few years, with a number of patent expiries and anticipated new drug approvals. The market for Alzheimer’s disease has not seen any recent major breakthroughs, and is expected to experience a decline due to the patent expiry of several major products. The market for Parkinson’s disease, on the other hand, is expected to experience growth due to the anticipated approval of expensive products such as Duodopa in the US, in spite of the fact that it will soon hit its own patent cliff. Additionally, the overall aging of populations the developed world is expected to increase the number of patients suffering from these diseases due to their relatively high prevalence in the elderly.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis, and key M&A and licensing deal trends in Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD). The report covers and includes -
- The current therapeutic environment in the treatment of AD, PD, HD and ALS across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan.
- Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations.
- Market forecasts for all four indications across the US, the top five countries in Europe (EU5) - Germany, France, the UK, Italy, and Spain- as well as Japan.
- Key market drivers and barriers
- The major deals that have taken place in the Neurodegenerative Diseases Market in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total value. A concomitant analysis of the licensing deal values for products by molecule types and is also provided.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Understand the competitive environment for Neurodegenerative Diseases
- Understand the clinical and commercial impact of major patent expiries in the neurodegenerative diseases markets
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the neurodegenerative diseases market in the forecast period
- Grasp the unmet need which exists in the neurodegenerative diseases Market
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps

Table Of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Neurodegenerative Diseases Market to 2018: Introduction 13
3 Neurodegenerative Diseases Market to 2018: Global Market Overview 14
3.1 Revenue 14
3.2 Treatment Usage Pattern 16
3.3 Distribution by Market 17
3.4 Drivers and Restraints of the Neurodegenerative Diseases Market 18
3.4.1 Drivers 18
3.4.2 Restraints 18
4 Therapeutic Landscape 19
4.1 Market for Alzheimer’s Disease 19
4.1.1 Introduction 19
4.1.2 Revenue and Forecasts 21
4.1.3 Treatment Usage Pattern 23
4.1.4 Geographical Landscape 24
4.1.5 Drivers and Restraints for the Alzheimer’s Disease Market 46
4.2 Market for Parkinson’s Disease 47
4.2.1 Introduction 47
4.2.2 Revenue and Forecasts 49
4.2.3 Treatment Usage Pattern 50
4.2.4 Geographical Landscape 51
4.2.5 Drivers and Restraints for the Parkinson’s Disease Market 73
4.3 Market for Amyotrophic Lateral Sclerosis 74
4.3.1 Introduction 74
4.3.2 Revenue and Forecasts 76
4.3.3 Treatment Usage Pattern 77
4.3.4 Geographical Landscape 78
4.3.5 Drivers and Restraints for the Amyotrophic Lateral Sclerosis Market 100
4.4 Market for Huntington’s Disease 101
4.4.1 Introduction 101
4.4.2 Revenue and Forecasts 103
4.4.3 Treatment Usage Pattern 104
4.4.4 Geographical Landscape 105
4.4.5 Drivers and Restraints for the Huntington’s Disease Market 127
5 Neurodegenerative Diseases Market: Pipeline Analysis 128
5.1 Introduction 128
5.2 Summary of the Current Neurodegenerative Diseases RandD Pipeline 129
5.2.1 Alzheimer's Disease 129
5.2.2 Amyotrophic Lateral Sclerosis 142
5.2.3 Parkinson’s Disease 147
5.2.4 Huntington’s Disease 155
6 Neurodegenerative Diseases Market: Deals and Strategic Consolidations 158
6.1 Merger and Acquisition Deals 158
6.1.1 Sanofi-Synthelabo Merges with Aventis 160
6.1.2 Bayer Acquires Schering 160
6.1.3 Takeda Pharma Completes Acquisition of Nycomed International for $13,681m 160
6.1.4 Teva Pharma Acquires Ivax 160
6.1.5 Abbott Labs Acquires Solvay Pharma 160
6.1.6 Teva Completes Acquisition of Cephalon for $6.8 billion 160
6.1.7 UCB Acquires 87.62% Stake in Schwarz Pharma 161
6.1.8 Biovail Acquires Valeant Pharma 161
6.1.9 Dainippon Sumitomo Pharma Completes Acquisition of Sepracor for $2.6 Billion 161
6.1.10 Merck Acquires Banyu Pharma 161
6.1.11 Amgen Completes Acquisition of Micromet for $1.2 Billion 161
6.1.12 Bayer Acquires Minority Stake in Bayer Schering Pharma 161
6.1.13 Daiichi Sankyo Completes Acquisition of Plexxikon 162
6.1.14 Lundbeck Acquires Ovation Pharma 162
6.1.15 Eli Lilly and Company Acquires Avid RadioPharma 162
6.1.16 Abbott Labs Completes Acquisition of Facet Biotech 162
6.1.17 Biogen Idec Acquires Fumapharm 162
6.1.18 Upsher-Smith Completes Acquisition of Remaining 84% Stake in Proximagen for up to $555m 163
6.1.19 Sun Pharma Acquires Controlling Stake in Taro Pharma 163
6.1.20 Pfizer Acquires Rinat Neuroscience 163
6.1.21 Cubist Pharma Completes Acquisition of Adolor for $415m 163
6.1.22 Biogen Idec Acquires Panima Pharma 164
6.1.23 Teva Pharma Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey 164
6.1.24 Fujifilm Holdings Acquires 66% Stake in Toyama Chemical 164
6.1.25 MGI PHARMA Acquires Guilford Pharma 164
6.1.26 H. Lundbeck Acquires LifeHealth 164
6.1.27 Endo Pharma Completes Acquisition of Penwest Pharma 165
6.1.28 EPIX Pharma Acquires Predix Pharma 165
6.1.29 Biogen Idec Acquires Syntonix Pharmaceuticals 165
6.1.30 Biotie Therapies Acquires Synosia Therapeutics 165
6.2 Licensing Agreements 166
6.2.1 Cephalon Enters into a Licensing Agreement with Mesoblast for Regenerative Medicine 167
6.2.2 Idera Pharma Enters into a Licensing Agreement with Merck 167
6.2.3 Astellas Pharma Enters into Licensing Agreement with CoMentis for Beta-Secretase Inhibitors 167
6.2.4 Synosia Therapeutics Enters into Licensing Agreement with UCB for SYN-115 and SYN-118 167
6.2.5 GlaxoSmithKline Signs an Agreement with AFFiRiS 168
6.2.6 Biogen Enters into an Agreement with Acorda Therapeutics 168
6.2.7 BioMS Medical Enters into Licensing Agreement with Eli Lilly 168
6.2.8 AC Immune Enters into Licensing Agreement with Genentech for Anti-Tau Antibodies 168
6.2.9 Biovail Enters into Licensing Agreement with Acadia Pharmaceuticals 168
6.2.10 Biogen Idec Enters into Licensing Agreement with Knopp Neurosciences for KNS-760704 169
6.2.11 AstraZeneca Enters into Licensing Agreement with Targacept 169
6.2.12 AC Immune Enters into Licensing Agreement with Genentech 169
6.2.13 Proximagen Enters into Licensing Agreement with Upsher-Smith Labs 169
6.2.14 Merck Serono Enters into Licensing Agreement with Apitope Technology 170
6.2.15 Serono Enters into Licensing Agreement with Newron Pharma for Safinamide 170
6.2.16 Shire Exercises Option to License Adenosine A2A from Heptares Therapeutics 170
6.2.17 GlaxoSmithKline Enters into Licensing Agreement with Impax Pharma for IPX066 170
6.2.18 Santhera Pharmaceuticals Enters into Licensing Agreement with Ipsen for Fipamezole 171
6.2.19 Domain Therapeutics Enters into Licensing Agreement with Merck Serono 171
6.2.20 Addex Pharma Enters into Collaboration and Licensing Agreement with Merck and Co 171
6.2.21 Curis Enters into Licensing Agreement with Wyeth Pharma 171
6.2.22 Pfizer Enters into a License and Collaboration Agreement with Transtech Pharma 171
6.2.23 Antisense Therapeutics Enters into Licensing Agreement with Teva Pharma 172
6.2.24 Biogen Idec Enters into Licensing Agreement with Vernalis 172
6.3 Co-Development Deals 173
6.3.1 GlaxoSmithKline Signs an Agreement with Targacept 174
6.3.2 GlaxoSmithKline Enters into an Agreement with EPIX Pharma 174
6.3.3 Evotec Enters into Co-Development Agreement with Roche 174
6.3.4 Pfizer Enters into Co-Development Agreement with Medivation for Dimebon 174
6.3.5 Alectos Therapeutics Enters into Research Collaboration with Merck and Co 174
6.3.6 Targacept Expands its Collaboration Agreement with AstraZeneca 175
6.3.7 Boehringer Ingelheim Partners with Vitae Pharma 175
6.3.8 Elan Enters into Co-Development Agreement with Transition Therapeutics 175
6.3.9 Ceregene Enters into Agreement with Genzyme 175
7 Appendix 176
7.1 Market Definitions 176
7.2 Abbreviations 176
7.3 Sources 177
7.4 Research Methodology 179
7.4.1 Coverage 180
7.4.2 Secondary Research 180
7.4.3 Primary Research 180
7.5 Therapeutic Landscape 181
7.5.1 Epidemiology-based Forecasting 181
7.5.2 Market Size by Geography 182
7.6 Geographical Landscape 183
7.7 Pipeline Analysis 184
7.8 Competitive Landscape 184
7.8.1 Expert Panel Validation 184
7.9 Contact Us 184
7.10 Disclaimer 184

List of Tables

Table 1: Neurodegenerative Diseases Market, Global, Revenue Forecast ($m), 2012-2018 14
Table 2: Neurodegenerative Diseases Market, Global, Revenue Forecast by Geography ($m), 2012-2018 15
Table 3: Neurodegenerative Diseases Market, Global, Treatment Usage Pattern (’000), 2012-2018 16
Table 4: Neurodegenerative Diseases Market, Global, Revenue Forecast by Market ($m), 2012-2018 17
Table 5: Alzheimer’s Disease Market, Global, Revenue Forecast ($m), 2012-2018 22
Table 6: Alzheimer’s Disease Market, Global, Treatment Usage Pattern (‘000), 2012-2018 23
Table 7: Alzheimer’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012-2018 24
Table 8: Alzheimer’s Disease Market, Global, Revenue Forecast ($m), 2012-2018 25
Table 9: Alzheimer’s Disease Market, US, Annual Cost of Therapy ($), 2012-2018 26
Table 10: Alzheimer’s Disease Market, US, Treatment Usage Pattern (‘000), 2012-2018 27
Table 11: Alzheimer’s Disease Market, UK, Revenue Forecast ($m), 2012-2018 28
Table 12: Alzheimer’s Disease Market, UK, Annual Cost of Therapy ($), 2012-2018 29
Table 13: Alzheimer’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012-2018 30
Table 14: Alzheimer’s Disease Market, Global, Revenue Forecast ($m), 2012-2018 31
Table 15: Alzheimer’s Disease Market, France, Annual Cost of Therapy ($), 2012-2018 32
Table 16: Alzheimer’s Disease Market, France, Treatment Usage Pattern (‘000), 2012-2018 33
Table 17: Alzheimer’s Disease Market, Germany, Revenue Forecast ($m), 2012-2018 34
Table 18: Alzheimer’s Disease Market, Germany, Annual Cost of Therapy ($), 2012-2018 35
Table 19: Alzheimer’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012-2018 36
Table 20: Alzheimer’s Disease Market, Italy, Revenue Forecast ($m), 2012-2018 37
Table 21: Alzheimer’s Disease Market, Italy, Annual Cost of Therapy ($), 2012-2018 38
Table 22: Alzheimer’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012-2018 39
Table 23: Alzheimer’s Disease Market, Spain, Revenue Forecast ($m), 2012-2018 40
Table 24: Alzheimer’s Disease Market, Spain, Annual Cost of Therapy ($), 2012-2018 41
Table 25: Alzheimer’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012-2018 42
Table 26: Alzheimer’s Disease Market, Japan, Revenue Forecast ($m), 2012-2018 43
Table 27: Alzheimer’s Disease Market, Japan, Annual Cost of Therapy ($), 2012-2018 44
Table 28: Alzheimer’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012-2018 45
Table 29: Parkinson’s Disease Market, Global, Revenue Forecast ($m), 2012-2018 49
Table 30: Parkinson’s Disease Market, Global, Treatment Usage Pattern (‘000), 2012-2018 50
Table 31: Parkinson’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012-2018 51
Table 32: Parkinson’s Disease Market, US, Revenue Forecast ($m), 2012-2018 52
Table 33: Parkinson’s Disease Market, US, Annual Cost of Therapy ($), 2012-2018 53
Table 34: Parkinson’s Disease Market, US, Treatment Usage Pattern (‘000), 2012-2018 54
Table 35: Parkinson’s Disease Market, UK, Revenue Forecast ($m), 2012-2018 55
Table 36: Parkinson’s Disease Market, UK, Annual Cost of Therapy ($), 2012-2018 56
Table 37: Parkinson’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012-2018 57
Table 38: Parkinson’s Disease Market, France, Revenue Forecast ($m), 2012-2018 58
Table 39: Parkinson’s Disease Market, France, Annual Cost of Therapy ($), 2012-2018 59
Table 40: Parkinson’s Disease Market, France, Treatment Usage Pattern (‘000), 2012-2018 60
Table 41: Parkinson’s Disease Market, Germany, Revenue Forecast ($m), 2012-2018 61
Table 42: Parkinson’s Disease Market, Germany, Annual Cost of Therapy ($), 2012-2018 62
Table 43: Parkinson’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012-2018 63
Table 44: Parkinson’s Disease Market, Italy, Revenue Forecast ($m), 2012-2018 64
Table 45: Parkinson’s Disease Market, Italy, Annual Cost of Therapy ($), 2012-2018 65
Table 46: Parkinson’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012-2018 66
Table 47: Parkinson’s Disease Market, Spain, Revenue Forecast ($m), 2012-2018 67
Table 48: Parkinson’s Disease Market, Spain, Annual Cost of Therapy ($), 2012-2018 68
Table 49: Parkinson’s Disease Market, Spain, Treatment Usage Pattern Forecast (‘000), 2012-2018 69
Table 50: Parkinson’s Disease Market, Japan, Revenue Forecast ($m), 2012-2018 70
Table 51: Parkinson’s Disease Market, Japan, Annual Cost of Therapy ($), 2012-2018 71
Table 52: Parkinson’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012-2018 72
Table 53: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast ($m), 2012-2018 76
Table 54: Amyotrophic Lateral Sclerosis Market, Global, Treatment Usage Pattern (‘000), 2010-2018 77
Table 55: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast by Geography ($m), 2012-2018 78
Table 56: Amyotrophic Lateral Sclerosis Market, US, Revenue Forecast ($m), 2012-2018 79
Table 57: Amyotrophic Lateral Sclerosis Market, US, Annual Cost of Therapy ($), 2012-2018 80
Table 58: Amyotrophic Lateral Sclerosis Market, US, Treatment Usage Pattern (‘000), 2012-2018 81
Table 59: Amyotrophic Lateral Sclerosis Market, UK, Revenue Forecast ($m), 2012-2018 82
Table 60: Amyotrophic Lateral Sclerosis Market, UK, Annual Cost of Therapy ($), 2012-2018 83
Table 61: Amyotrophic Lateral Sclerosis Market, UK, Treatment Usage Pattern (‘000), 2012-2018 84
Table 62: Amyotrophic Lateral Sclerosis Market, France, Revenue Forecast ($m), 2012-2018 85
Table 63: Amyotrophic Lateral Sclerosis Market, France, Annual Cost of Therapy ($), 2012-2018 86
Table 64: Amyotrophic Lateral Sclerosis Market, France, Treatment Usage Pattern (‘000), 2012-2018 87
Table 65: Amyotrophic Lateral Sclerosis Market, Germany, Revenue Forecast ($m), 2012-2018 88
Table 66: Amyotrophic Lateral Sclerosis Market, Germany, Annual Cost of Therapy ($), 2012-2018 89
Table 67: Amyotrophic Lateral Sclerosis Market, Germany, Treatment Usage Pattern (‘000), 2012-2018 90
Table 68: Amyotrophic Lateral Sclerosis Market, Italy, Revenue Forecast ($m), 2012-2018 91
Table 69: Amyotrophic Lateral Sclerosis Market, Italy, Annual Cost of Therapy ($), 2012-2018 92
Table 70: Amyotrophic Lateral Sclerosis Market, Italy, Treatment Usage Pattern (‘000), 2012-2018 93
Table 71: Amyotrophic Lateral Sclerosis Market, Spain, Revenue Forecast ($m), 2012-2018 94
Table 72: Amyotrophic Lateral Sclerosis Market, Spain, Annual Cost of Therapy ($), 2012-2018 95
Table 73: Amyotrophic Lateral Sclerosis Market, Spain, Treatment Usage Pattern (‘000), 2012-2018 96
Table 74: Amyotrophic Lateral Sclerosis Market, Japan, Revenue Forecast ($m), 2012-2018 97
Table 75: Amyotrophic Lateral Sclerosis Market, Japan, Annual Cost of Therapy ($), 2012-2018 98
Table 76: Amyotrophic Lateral Sclerosis Market, Japan, Treatment Usage Pattern (‘000), 2012-2018 99
Table 77: Huntington’s Disease Market, Global, Revenue Forecast ($m), 2012-2018 103
Table 78: Huntington’s Disease Market, Global, Treatment Usage Pattern (‘000), 2012-2018 104
Table 79: Huntington’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012-2018 105
Table 80: Huntington’s Disease Market, US, Revenue Forecast ($m), 2012-2018 106
Table 81: Huntington’s Disease Market, US, Annual Cost of Therapy ($), 2012-2018 107
Table 82: Huntington’s Disease Market, US, Treatment Usage Pattern (‘000), 2012-2018 108
Table 83: Huntington’s Disease Market, UK, Revenue Forecast ($m), 2012-2018 109
Table 84: Huntington’s Disease Market, UK, Annual Cost of Therapy ($), 2012-2018 110
Table 85: Huntington’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012-2018 111
Table 86: Huntington’s Disease Market, France, Revenue Forecast ($m), 2012-2018 112
Table 87: Huntington’s Disease Market, France, Annual Cost of Therapy ($), 2012-2018 113
Table 88: Huntington’s Disease Market, France, Treatment Usage Pattern (‘000), 2012-2018 114
Table 89: Huntington’s Disease Market, Germany, Revenue Forecast ($m), 2012-2018 115
Table 90: Huntington’s Disease Market, Germany, Annual Cost of Therapy ($), 2012-2018 116
Table 91: Huntington’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012-2018 117
Table 92: Huntington’s Disease Market, Italy, Revenue Forecast ($m), 2012-2018 118
Table 93: Huntington’s Disease Market, Italy, Annual Cost of Therapy ($), 2012-2018 119
Table 94: Huntington’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012-2018 120
Table 95: Huntington’s Disease Market, Spain, Revenue Forecast ($m), 2012-2018 121
Table 96: Huntington’s Disease Market, Spain, Annual Cost of Therapy ($), 2012-2018 122
Table 97: Huntington’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012-2018 123
Table 98: Huntington’s Disease Market, Japan, Revenue Forecast ($m), 2012-2018 124
Table 99: Huntington’s Disease Market, Japan, Annual Cost of Therapy ($), 2012-2018 125
Table 100: Huntington’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012-2018 126
Table 101: Neurodegenerative Diseases Market, Global, Alzheimer’s Disease Product Pipeline, 2012 129
Table 102: Neurodegenerative Diseases Market, Global, Amyotrophic Lateral Sclerosis Product Pipeline, 2012 142
Table 103: Neurodegenerative Diseases Market, Global, Parkinson’s Disease Product Pipeline, 2012 147
Table 104: Neurodegenerative Diseases Market, Global, Huntington’s Disease Product Pipeline, 2012 155

List of Figures

Figure 1: Neurodegenerative Diseases Market, Global, Revenue Forecast ($m), 2012-2018 14
Figure 2: Neurodegenerative Diseases Market, Global, Revenue Forecast by Geography ($m), 2012 and 2018 15
Figure 3: Neurodegenerative Diseases Market, Global, Treatment Usage Pattern (’000), 2012-2018 16
Figure 4: Neurodegenerative Diseases Market, Global, Revenue Forecast by Market (%), 2012 and 2018 17
Figure 5: Alzheimer’s Disease Market, Global, Revenue Forecast ($m), 2012-2018 22
Figure 6: Alzheimer’s Disease Market, Global, Treatment Usage Pattern (’000), 2012-2018 23
Figure 7: Alzheimer’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012 and 2018 24
Figure 8: Alzheimer’s Disease Market, US, Revenue Forecast ($m), 2012-2018 25
Figure 9: Alzheimer’s Disease Market, US, Annual Cost of Therapy ($), 2012-2018 26
Figure 10: Alzheimer’s Disease Market, US, Treatment Usage Pattern (‘000), 2012-2018 27
Figure 11: Alzheimer’s Disease Market, UK, Revenue Forecast ($m), 2012-2018 28
Figure 12: Alzheimer’s Disease Market, UK, Annual Cost of Therapy ($), 2012-2018 29
Figure 13: Alzheimer’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012-2018 30
Figure 14: Alzheimer’s Disease Market, France, Revenue Forecast ($m), 2012-2018 31
Figure 15: Alzheimer’s Disease Market, France, Annual Cost of Therapy ($), 2012-2018 32
Figure 16: Alzheimer’s Disease Market, France, Treatment Usage Pattern (‘000), 2012-2018 33
Figure 17: Alzheimer’s Disease Market, Germany, Revenue Forecast ($m), 2004-2018 34
Figure 18: Alzheimer’s Disease Market, Germany, Annual Cost of Therapy ($), 2012-2018 35
Figure 19: Alzheimer’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012-2018 36
Figure 20: Alzheimer’s Disease Market, Italy, Revenue Forecast ($m), 2012-2018 37
Figure 21: Alzheimer’s Disease Market, Italy, Annual Cost of Therapy ($), 2012-2018 38
Figure 22: Alzheimer’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012-2018 39
Figure 23: Alzheimer’s Disease Market, Spain, Revenue Forecast ($m), 2012-2018 40
Figure 24: Alzheimer’s Disease Market, Spain, Annual Cost of Therapy ($), 2012-2018 41
Figure 25: Alzheimer’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012-2018 42
Figure 26: Alzheimer’s Disease Market, Japan, Revenue Forecast ($m), 2012-2018 43
Figure 27: Alzheimer’s Disease Market, Japan, Annual Cost of Therapy ($), 2012-2018 44
Figure 28: Alzheimer’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012-2018 45
Figure 29: Parkinson’s Disease Market, Global, Revenue Forecast ($m), 2012-2018 49
Figure 30: Parkinson’s Disease Market Global, Treatment Usage Pattern (‘000), 2012-2018 50
Figure 31: Parkinson’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012-2018 51
Figure 32: Parkinson’s Disease Market, US, Revenue Forecast ($m), 2012-2018 52
Figure 33: Parkinson’s Disease Market, US, Annual Cost of Therapy ($), 2012-2018 53
Figure 34: Parkinson’s Disease Market, US, Treatment Usage Pattern (‘000), 2012-2018 54
Figure 35: Parkinson’s Disease Market, UK, Revenue Forecast ($m), 2012-2018 55
Figure 36: Parkinson’s Disease Market, UK, Annual Cost of Therapy ($), 2012-2018 56
Figure 37: Parkinson’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012-2018 57
Figure 38: Parkinson’s Disease Market, France, Revenue Forecast ($m), 2012-2018 58
Figure 39: Parkinson’s Disease Market, France, Annual Cost of Therapy ($), 2012-2018 59
Figure 40: Parkinson’s Disease Market, France, Treatment Usage Pattern (‘000), 2012-2018 60
Figure 41: Parkinson’s Disease Market, Germany, Revenue Forecast ($m), 2012-2018 61
Figure 42: Parkinson’s Disease Market, Germany, Annual Cost of Therapy ($), 2012-2018 62
Figure 43: Parkinson’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012-2018 63
Figure 44: Parkinson’s Disease Market, Italy, Revenue Forecast ($m), 2012-2018 64
Figure 45: Parkinson’s Disease Market, Italy, Annual Cost of Therapy ($), 2012-2018 65
Figure 46: Parkinson’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012-2018 66
Figure 47: Parkinson’s Disease Market, Spain, Revenue Forecast ($m), 2012-2018 67
Figure 48: Parkinson’s Disease Market, Spain, Annual Cost of Therapy ($), 2012-2018 68
Figure 49: Parkinson’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012-2018 69
Figure 50: Parkinson’s Disease Market, Japan, Revenue Forecast ($m), 2012-2018 70
Figure 51: Parkinson’s Disease Market, Japan, Annual Cost of Therapy ($), 2012-2018 71
Figure 52: Parkinson’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012-2018 72
Figure 53: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast ($m), 2012-2018 76
Figure 54: Amyotrophic Lateral Sclerosis Market, Global, Treatment Usage Pattern (‘000), 2012-2018 77
Figure 55: Amyotrophic Lateral Sclerosis Market, Global, Revenue Forecast by Geography ($m), 2012-2018 78
Figure 56: Amyotrophic Lateral Sclerosis Market, US, Revenue Forecast ($m), 2012-2018 79
Figure 57: Amyotrophic Lateral Sclerosis Market, US, Annual Cost of Therapy ($), 2012-2018 80
Figure 58: Amyotrophic Lateral Sclerosis Market, US, Treatment Usage Pattern (‘000), 2012-2018 81
Figure 59: Amyotrophic Lateral Sclerosis Market, UK, Revenue Forecast ($m), 2012-2018 82
Figure 60: Amyotrophic Lateral Sclerosis Market, UK, Annual Cost of Therapy ($), 2012-2018 83
Figure 61: Amyotrophic Lateral Sclerosis Market, UK, Treatment Usage Pattern (‘000), 2012-2018 84
Figure 62: Amyotrophic Lateral Sclerosis Market, France, Revenue Forecast ($m), 2012-2018 85
Figure 63: Amyotrophic Lateral Sclerosis Market, France, Annual Cost of Therapy ($), 2012-2018 86
Figure 64: Amyotrophic Lateral Sclerosis Market, France, Treatment Usage Pattern (‘000), 2012-2018 87
Figure 65: Amyotrophic Lateral Sclerosis Market, Germany, Revenue Forecast ($m), 2012-2018 88
Figure 66: Amyotrophic Lateral Sclerosis Market, Germany, Annual Cost of Therapy ($), 2012-2018 89
Figure 67: Amyotrophic Lateral Sclerosis Market, Germany, Treatment Usage Pattern (‘000), 2012-2018 90
Figure 68: Amyotrophic Lateral Sclerosis Market, Italy, Revenue Forecast ($m), 2012-2018 91
Figure 69: Amyotrophic Lateral Sclerosis Market, Italy, Annual Cost of Therapy ($), 2012-2018 92
Figure 70: Amyotrophic Lateral Sclerosis Market, Italy, Treatment Usage Pattern (‘000), 2012-2018 93
Figure 71: Amyotrophic Lateral Sclerosis Market, Spain, Revenue Forecast ($m), 2012-2018 94
Figure 72: Amyotrophic Lateral Sclerosis Market, Spain, Annual Cost of Therapy ($), 2012-2018 95
Figure 73: Amyotrophic Lateral Sclerosis Market, Spain, Treatment Usage Pattern (‘000), 2012-2018 96
Figure 74: Amyotrophic Lateral Sclerosis Market, Japan, Revenue Forecast ($m), 2012-2018 97
Figure 75: Amyotrophic Lateral Sclerosis Market, Japan, Annual Cost of Therapy ($), 2012-2018 98
Figure 76: Amyotrophic Lateral Sclerosis Market, Japan, Treatment Usage Pattern (‘000), 2012-2018 99
Figure 77: Huntington’s Disease Market, Global, Revenue Forecast ($m), 2012-2018 103
Figure 78: Huntington’s Disease Market, Global, Treatment Usage Pattern (‘000), 2012-2018 104
Figure 79: Huntington’s Disease Market, Global, Revenue Forecast by Geography ($m), 2012-2018 105
Figure 80: Huntington’s Disease Market, US, Revenue Forecast ($m), 2012-2018 106
Figure 81: Huntington’s Disease Market, US, Annual Cost of Therapy ($), 2012-2018 107
Figure 82: Huntington’s Disease Market, US, Treatment Usage Pattern (‘000), 2012-2018 108
Figure 83: Huntington’s Disease Market, UK, Revenue Forecast ($m), 2012-2018 109
Figure 84: Huntington’s Disease Market, UK, Annual Cost of Therapy ($), 2012-2018 110
Figure 85: Huntington’s Disease Market, UK, Treatment Usage Pattern (‘000), 2012-2018 111
Figure 86: Huntington’s Disease Market, France, Revenue Forecast ($m), 2012-2018 112
Figure 87: Huntington’s Disease Market, France, Annual Cost of Therapy ($), 2012-2018 113
Figure 88: Huntington’s Disease Market, France, Treatment Usage Pattern (‘000), 2012-2018 114
Figure 89: Huntington’s Disease Market, Germany, Revenue Forecast ($m), 2012-2018 115
Figure 90: Huntington’s Disease Market, Germany, Annual Cost of Therapy ($), 2012-2018 116
Figure 91: Huntington’s Disease Market, Germany, Treatment Usage Pattern (‘000), 2012-2018 117
Figure 92: Huntington’s Disease Market, Italy, Revenue Forecast ($m), 2012-2018 118
Figure 93: Huntington’s Disease Market, Italy, Annual Cost of Therapy ($), 2012-2018 119
Figure 94: Huntington’s Disease Market, Italy, Treatment Usage Pattern (‘000), 2012-2018 120
Figure 95: Huntington’s Disease Market, Spain, Revenue Forecast ($m), 2012-2018 121
Figure 96: Huntington’s Disease Market, Spain, Annual Cost of Therapy ($), 2012-2018 122
Figure 97: Huntington’s Disease Market, Spain, Treatment Usage Pattern (‘000), 2012-2018 123
Figure 98: Huntington’s Disease Market, Japan, Revenue Forecast ($m), 2012-2018 124
Figure 99: Huntington’s Disease Market, Japan, Annual Cost of Therapy ($), 2012-2018 125
Figure 100: Huntington’s Disease Market, Japan, Treatment Usage Pattern (‘000), 2012-2018 126
Figure 101: Neurodegenerative Diseases Market, Global, Product Pipeline by Indication (%), 2012 128
Figure 102: Neurodegenerative Diseases Market, Global, Product Pipeline by Phase (%), 2012 128
Figure 103: Neurodegenerative Diseases Market, Global, Mergers and Acquisition Deals, 2004-2012 158
Figure 104: Neurodegenerative Diseases Market, Global, Mergers and Acquisition Deals, 2004-2012 159
Figure 105: Neurodegenerative Diseases Market, Licensing Agreements, 2004-2012 166
Figure 106: Neurodegenerative Diseases Market, Licensing Agreements (%), 2004-2012 166
Figure 107: Neurodegenerative Diseases Market, Co-Development Agreements, 2004-2012 173
Figure 108: Neurodegenerative Diseases Market, Co-Development Agreements (%), 2004-2012 173
Figure 109: GBI Research Market Forecasting Model 183

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.